Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistance prostate cancer.
EP: 1.Metastatic Prostate Cancer: Background and Patient Prognosis
EP: 2.Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer
EP: 3.Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life
EP: 4.Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis
EP: 5.Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer
EP: 6.Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
EP: 7.Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer
Study finds only half of patients undergoing 24-hour urine tests receive complete testing
December 14th 2022“One of the goals of this study was to look at whether 24-hour urine testing in the VA population included all the important components of 24-hour urine panel testing,” says Ryan Hsi, MD, FACS.
Study finds inadequate patient education for scheduled urologic procedures
October 19th 2022Researchers at Albert Einstein College of Medicine found patients benefited from a pre-procedural interview to educate them about the risks, benefits, and alternatives to urologic treatments they were scheduled to receive.
